InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million.

InterCure Ltd, a cannabis company, has announced its preliminary estimated revenue for the full year of 2023. The company expects to have annual revenue of NIS 351 million and EBITDA of over NIS 50 million. They have also expanded their branded products portfolio and entered into an exclusive partnership agreement with TYSON 2.0. However, the company has faced challenges due to the war situation declared by the Israeli government, which has limited access to their Southern Israel Site. They are working with the Israeli authorities to obtain compensation for the damages caused. Additionally, InterCure plans to launch its products in Germany in the near future. [Extracted from the article]